Citigroup
CUE icon

Citigroup’s Cue Biopharma CUE Stock Holding History

Citigroup’s Portfolio CUE Stock Details CUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$80.7K Buy
3,119
+3,118
+311,800% +$92.5K ﹤0.01% 4546
2026
Q2 		$32 Buy
+1
New +$23 ﹤0.01% 5556
2025
Q4 		– Sell
-4
Closed -$95 – 6136
2025
Q3 		$95 Buy
+4
New +$94 ﹤0.01% 5813
2025
Q1 		– Sell
-1
Closed -$47 – 5664
2024
Q4 		$47 Hold
1
– – ﹤0.01% 5717
2024
Q3 		$33 Sell
1
-167
-99% -$3.62K ﹤0.01% 5581
2024
Q2 		$6.26K Sell
168
-34
-17% -$1.68K ﹤0.01% 5225
2024
Q1 		$11.5K Buy
202
+16
+9% +$1.13K ﹤0.01% 5169
2023
Q4 		$14.7K Buy
186
+185
+18,500% +$13.2K ﹤0.01% 5088
2023
Q3 		$80 Sell
1
-342
-100% -$33.4K ﹤0.01% 5455
2023
Q2 		$37.6K Buy
+343
New +$40.3K ﹤0.01% 4782
2022
Q3 		– Sell
-10
Closed -$1K – 5904
2022
Q2 		$1K Sell
10
-57
-85% -$6.67K ﹤0.01% 6000
2022
Q1 		$10K Sell
67
-2,606
-97% -$553K ﹤0.01% 5523
2021
Q4 		$907K Buy
2,673
+1,733
+184% +$670K ﹤0.01% 3355
2021
Q3 		$411K Sell
940
-1,831
-66% -$639K ﹤0.01% 3746
2021
Q2 		$968K Buy
2,771
+296
+12% +$115K ﹤0.01% 3257
2021
Q1 		$906K Buy
2,475
+2,275
+1,138% +$936K ﹤0.01% 3057
2020
Q4 		$75K Buy
200
+119
+147% +$47.6K ﹤0.01% 5761
2020
Q3 		$36K Sell
81
-1,453
-95% -$837K ﹤0.01% 5793
2020
Q2 		$1.13M Buy
1,534
+1,332
+659% +$965K ﹤0.01% 3437
2020
Q1 		$86K Buy
202
+67
+50% +$32.5K ﹤0.01% 5471
2019
Q4 		$65K Sell
135
-343
-72% -$108K ﹤0.01% 6105
2019
Q3 		$121K Sell
478
-86
-15% -$20.7K ﹤0.01% 5528
2019
Q2 		$152K Buy
564
+4
+0.7% +$995 ﹤0.01% 5504
2019
Q1 		$130K Sell
560
-13
-2% -$2.47K ﹤0.01% 5499
2018
Q4 		$80K Sell
573
-221
-28% -$40.1K ﹤0.01% 5843
2018
Q3 		$216K Buy
794
+77
+11% +$22.2K ﹤0.01% 5168
2018
Q2 		$255K Sell
717
-1,152
-62% -$458K ﹤0.01% 4803
2018
Q1 		$788K Buy
+1,869
New +$852K ﹤0.01% 3487

Other funds holding CUE

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Robertson Stephens Wealth Management
Robertson Stephens Wealth Management San Francisco, California $4.14B AUM 13.63% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $500B AUM 36.84% 1-Year Est. Return
US Bancorp
US Bancorp Minneapolis, Minnesota $92B AUM 22.91% 1-Year Est. Return
SBI Securities
SBI Securities Tokyo, Japan $4.38B AUM 56.37% 1-Year Est. Return
Gleason Group
Gleason Group Prospect, Kentucky $1.13B AUM 12.68% 1-Year Est. Return
Newbridge Financial Services Group
Newbridge Financial Services Group Boca Raton, Florida $868M AUM 42.47% 1-Year Est. Return
Golden State Wealth Management
Golden State Wealth Management Santa Ana, California $1.1B AUM 19.2% 1-Year Est. Return
Mather Group
Mather Group Chicago, Illinois $11.8B AUM 12.84% 1-Year Est. Return
Physician Wealth Advisors
Physician Wealth Advisors Midvale, Utah $869M AUM 17.6% 1-Year Est. Return

Citigroup's CUE Position: Q3 2026 in Review

Citigroup increased its Cue Biopharma (CUE) stake by 311,800% in Q3 2026, buying an estimated $92.5K and bringing the position to 3,119 shares worth $80.7K. The position accounts for ﹤0.01% of the portfolio, ranked #4546.

Citigroup first reported a position in CUE in Q1 2018 and has held it in 28 quarters since. The position peaked at $1.13M in Q2 2020. 12 funds tracked by Wall St. Rank hold CUE as of Q3 2026.

  • Citigroup held 3,119 shares of Cue Biopharma worth $80.7K as of Q3 2026.
  • Citigroup bought 3,118 Cue Biopharma shares in Q3 2026, an estimated $92.5K.
  • Cue Biopharma made up ﹤0.01% of Citigroup's portfolio in Q3 2026, its #4546 holding.
  • Citigroup first reported a position in Cue Biopharma in Q1 2018 and has held it in 28 quarters since.
  • Citigroup's Cue Biopharma position peaked at $1.13M in Q2 2020.
  • 12 funds tracked by Wall St. Rank held Cue Biopharma as of Q3 2026.

Based on Citigroup's 13F filing for Q3 2026, filed 4 Nov 2026.